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Abstract
Since guidelines on antibiotic drug treatment often focus on
appropriate first choice drugs, assessment of guideline
adherence should only concentrate on the first drug
prescribed, and not on subsequent antibiotics prescribed
after failure of the first one.
Purpose To determine a valid cut-off point for a definition
of “first” or “new” prescription in indicators for the
assessment of the quality of antibiotic drug treatment on
the basis of pharmaceutical data.
Methods Three possible definitions for the term “new
prescription” were compared, based on three different
periods of time, viz. more than 35, 28, or 21 days after
starting a previous antibiotic. In an observational study,
1,225 antimicrobial prescriptions from the medical files of
five family practices were audited (“clinical classification”)
and compared with a classification based on the three
definitions (“technical classification”). Agreement between
these clinical and technical classifications was determined
by calculating Cohen’s kappa. The technical classification
was analyzed as a diagnostic test, using the clinical
classification as the gold standard, and sensitivity, specificity,
likelihood ratios, and post-test probabilities were calculated.
Results Defining “new prescription” as “more than 35 days
after a previous prescription was issued” resulted in a
Cohen’s kappa of 0.93 (95% CI 0.92–0.98). The diagnostic
value of this definition was extremely high, with a
sensitivity of 0.976, specificity of 0.987, positive likelihood
ratio of 77.7, and negative likelihood ratio of 0.02.
Conclusion We recommend using a cut-off value of 35 days
since the last antimicrobial prescription as the definition of
a “new prescription” when no diagnostic information is
available, i.e., when using pharmaceutical data to assess the
quality of antibiotic prescribing behavior.
Keywords Quality indicators, health care . Primary health
care . Prescriptions . Guideline adherence
Introduction
Resistance of microorganisms to antimicrobials is an
increasing problem worldwide, posing a potential threat to
public health [1]. The European Surveillance of Antimicro-
bial Consumption (ESAC; www.ua.ac.be/ESAC) project,
funded by the European Commission, has collected data on
the use of antibiotics in Europe since 2001. Several of their
studies found that higher consumption of antibiotics corre-
lates strongly with high rates of resistance [2]. General
practitioners play a key role in fighting antimicrobial
resistance, since they provide 80% of all prescriptions of
antibiotics in human medicine [3]. In addition, veterinarian
use of antibiotics in Western Europe is also accountable for a
major part of the total volume of antibiotics used [4], and it
is especially the nontherapeutic use of antibiotics as growth
promoters which may have played an important part in the
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development of antimicrobial resistance, although some
authors doubt this [5]. The use of antimicrobial growth
promoters was prohibited in the beginning of 2006, but this
issue is beyond the scope of the present article.
To minimize antimicrobial resistance, general practi-
tioners are recommended to adhere to the clinical practice
guidelines on antibiotics. Guidelines on prescribing antimi-
crobial drugs focus on the type of antibiotics that should be
used as a treatment of first choice and the types that should
be avoided as first choice treatment. Only a few guidelines
also mention what choice should be made after failure of
the initial treatment.
In situations where one evaluates individual prescrip-
tions and with the availability of a diagnosis it might be
possible to detect whether a prescription is the first one
or a subsequent after failure of the first, and so whether
the choices made are appropriate. However, with the use
of a pharmaceutical database that lacks information about
diagnosis this is not possible. When studying all
prescriptions in a given period, however, one could
detect what proportion of the first prescriptions are in
line with guidelines. This means that when assessing the
guideline adherence in antibiotic drug treatment in a
pharmaceutical database, only those prescriptions that
represent the first antibiotic treatment for a disease/
diagnosis (“first” or “new” prescriptions) should be taken
into account.
In the context of a regional quality improvement project,
we developed a set of quality indicators that measure
guideline adherence regarding the prescription of antimi-
crobial drugs by general practitioners. Our indicators are
derived from 12 guidelines by the Dutch College of
General Practitioners and have been validated by a panel
of experts using the RAND-UCLA method [7], covering
face and content validity.
One option for assessing guideline adherence is to use
pharmaceutical databases [6]. Since these databases lack
diagnostic information, however, we used a predefined
minimum number of days between the current prescription
and an earlier antibiotic prescription as a proxy measure to
determine whether the current prescription should be
regarded as first or new and should be taken into account
when assessing the quality of prescribing.
The prescribing quality indicators are applied to a large
pharmaceutical database containing PACT (prescribing
analyses and cost) data. Pharmacists in the Netherlands
charge all delivered drugs to health insurance companies.
Their accounts include information about the patient (age
and sex), the prescriber, and the drug [8, 9]. General
practitioners do not, however, provide information on
indications/diagnoses to pharmacists, due to autonomy
considerations. We collected data from two major health
insurance companies in the southern part of the Netherlands,
which meant that huge quantities of information on all drugs
supplied in 1 year were available for analysis.
In four of our indicators, we encountered problems
relating to the definition of a “new prescription” (Table 1).
If the period of time since the previous prescription that is
used in our indicator is too short, many prescriptions that
are in fact second choice prescriptions for the same
indication/diagnosis, after failure of the first treatment,
would incorrectly be labeled as new prescriptions by our
indicator. If the period of time is too long, many new
prescriptions will be missed in the calculation of the
indicator score. In this study we therefore tried to determine
after what period of time (21, 28, or 35 days) it is safe to
assume that a prescription of antibiotics is new, i.e., it is the
first prescription for a new indication. We investigated this
by comparing the pharmaceutical data with information
from the medical files of patients kept by five family
practices.
Methods
Study design
In a cross-sectional observational study, a random sample
of prescriptions of antimicrobial drugs was taken from
patient files for 2008 kept by family physicians. We used
these prescriptions to calculate how the four indicators
containing the phrase “new prescription” (Table 1) would
classify each prescription, using different definitions of
the period since the previous prescription (35, 28,
21 days).
Population
A total of 1,225 antibiotics prescriptions were retrieved
from five family practices in the south of the Netherlands.
All practices are participating in a registration network for
general practitioners (RNH) managed by the University of
Maastricht [10]. Four of them were group practices
including at least three doctors, both men and women,
with different years of clinical experience. One practice was
run by a single female general practitioner.
Variables
The indications for the prescription of all examined
antibiotics prescriptions were determined from the medical
files. We also recorded whether the prescription was the
first antibiotic treatment for the diagnosis (“clinical classi-
fication”). We then assessed how the three different
definitions of “new prescription” would have classified
the prescription at stake (“technical classification”).
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Data collection
A senior medical student with sufficient medical knowledge
visited the five practices. The electronic medical records
were used to select antimicrobial drug prescriptions from
2008, taking a random sample from these lists of
prescriptions, to limit the workload. For each prescription
of an antimicrobial drug, the corresponding part of the
medical record was extracted and made anonymous. The
following items were recorded:
& Is the prescription the first antimicrobial prescription for
this diagnosis according to the medical judgment of the
investigator?
& Would the indicator definitions have classified this
antimicrobial prescription as new or not?
The first practice visited was used as a trial for the
procedure, to see whether any problems would arise with
the interpretation of the medical files. This meant that more
prescriptions (n=505, about 1/3 of all 1,792 antibiotic
prescriptions for 2008) were audited in this first practice
than in the other practices. All records were also assessed
by the first author, a general practitioner with more than
20 years of experience. Since no unforeseen problems were
encountered, the results of the first practice were included
in the analysis.
A fixed total number of 180 prescriptions were audited
in each of the remaining three practices. These included 90
prescriptions for indicators 1–3 (30 prescriptions for each
indicator) and 90 for indicator 4. Since indicator 4 includes
three different types of antibiotics, and we wanted to ensure
sufficient numbers per subgroup (not analyzed in this
paper), 30 files per antibiotic type were audited for this
indicator, so 90 in all.
Analysis
The results of the scoring forms for all practices were
pooled for each indicator and for each definition, and
entered into a 2×2 table. Cohen’s kappa and the
corresponding 95% confidence interval were then deter-
mined to estimate the agreement between the “technical
classification” (i.e., the calculation of an indicator score
based on a pharmaceutical database) and the “clinical
classification,” based on knowledge of the medical file, as
to whether a prescription should be seen as “new.”
We also analyzed the data by considering the technical
classification as a diagnostic test, using the clinical
classification as the gold standard, and calculated the
sensitivity, specificity, likelihood ratios (LR), and post-test
probabilities of this technical classification.
Results
The audit of the first practice related to 505 prescriptions,
those of the remaining practices to 720 prescriptions. For
each of these 1,225 prescriptions, we determined whether
the indicator would classify them as “new” (first) or “not
new” (not first). According to the assessment of the medical
files by the investigators, there were 962 new antimicrobial
prescriptions for which the period of time after the previous
prescription of an antibiotic drug was more than 35 days.
There were only two prescriptions that had been issued
more than 35 days after an earlier prescription but which
were in fact not new (i.e., related to the same diagnosis as
the previous prescription). These prescriptions were incor-
rectly classified as “new” by the indicators, regardless of
which of the three definitions was used. Table 2 shows how
these numbers changed when different periods of time were
used in the definition of a “new” prescription. Extending
the chosen period to 42 or even 49 days only added two
new prescriptions that were missed otherwise (data not
shown).
The results of all practices were pooled for each
indicator and for each period of time used in the definition,
and a Cohen’s kappa and 95% confidence interval could be
determined (Table 3). Results for each indicator showed
Table 1 Four indicators containing the term “new prescription”
No. Description Numerator (N) Denominator (D) Indicator
1 Minimize prescribing of
amoxicillin in combination with clavulanic
acid as an antibiotic of first choice
All new prescriptions of
amoxicillin in combination
with clavulanic acid
All new prescriptions
of antimicrobial drugs
1 − (N/D)
2 Minimize prescribing of macrolides
as an antibiotic of first choice
All new prescriptions of
macrolides
All new prescriptions
of antimicrobial drugs
1 − (N/D)
3 Minimize prescribing of quinolones
as an antibiotic of first choice
All new prescriptions of
quinolones
All new prescriptions
of antimicrobial drugs
1 − (N/D)
4 Preferably prescribe amoxicillin,
doxycyclin, and nitrofurantoin
as antibiotics of first choice
All new prescriptions of
amoxicillin, doxycyclin,
and nitrofurantoin
All new prescriptions of
antimicrobial drugs
N/D
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that the classification of new prescriptions agreed best with
the classification based on the medical data if the definition
involved a minimum of 35 days after a previous antimi-
crobial drug prescription. Of the 986 new prescriptions, 962
(97.6%) were correctly identified by the indicators as new,
while 24 (2.4%) were incorrectly identified as not new. Of
the 239 not-new prescriptions, 236 (98.7%) were correctly
identified by the indicators as not new, and 2 (1.3%) were
incorrectly identified as new.
We also analyzed the data by considering the technical
classification as a diagnostic test, using the clinical
classification as a gold standard, and calculating sensitivity,
specificity, and likelihood ratios for the three different
operationalizations (Table 4). The 21-day definition had a
sensitivity of 0.988, a specificity of 0.788, an LR+ of 4.6,
and an LR− of 0.015. The 28-day definition had a
sensitivity of 0.980, a specificity of 0.904, an LR+ of
10.2, and an LR− of 0.022. The 35-day definition had a
sensitivity of 0.976, a specificity of 0.987, an LR+ of 77.7,
and an LR− of 0.025.
Given a pre-test probability of an antibiotic prescription
being new of 80.5%, the post-test probabilities for positive
test results were 94.9, 97.6, and 99.7% for the 21-, 28-, and
35-day definitions, respectively, and the post-test probabil-
ities for negative test results were 0.38, 0.55, and 0.61%,
respectively.
Discussion
We developed a set of indicators of the quality of doctors’
prescribing behavior in the context of a regional project to
measure guideline adherence in general practice, using a
pharmaceutical database. The validity and accuracy of such
quality indicators must be guaranteed to enable the quality
of health care to be assessed. In addition to aspects such as
face and content validity, problems arose with four of the
indicators concerning the definition of the term “new
prescription” in relation to antimicrobial drugs, in the sense
that a “new” antimicrobial drug has to be the first treatment
for a given diagnosis. Practically speaking, this means that
there should be a certain minimum period of time between
the “new” prescription and the time when the previous
antimicrobial prescription was issued. We examined the
effect of three different periods of time (35, 28, and
21 days) for this definition by auditing medical files in
five family practices in the south of the Netherlands and
calculating which period would best allow our indicators to
Medical file Total
New Not new
Classified by indicator using 35 days definition New 962 3 965
Not new 24 236 260
Total 986 239 1,225
Classified by indicator using 28 days definition New 966 23 989
Not new 20 216 236
Total 986 239 1,225
Classified by indicator using 21 days definition New 974 51 1,025
Not new 12 188 200
Total 986 239 1,225
Table 2 2×2 tables of all pre-
scriptions audited. All prescrip-
tions in the selected patient files
were compared with our indica-
tors using three different defini-
tions of “new prescription”
(>35, >28, and >21 days after
the previous antimicrobial
prescription)
Table 3 Cohen’s kappa with confidence interval for each indicator, defining a “new prescription” as one issued 21, 28, and 35 days after a
previous one (n=number of prescriptions analyzed)
Indicator Type of antibiotic 21 days 28 days 35 days
Cohen’s kappa 95% CI Cohen’s kappa 95% CI Cohen’s kappa 95% CI
1 Amoxicillin with clavulanic acid (n=197) 0.90 0.83–0.97 0.93 0.87–0.99 0.99 0.96–1.00
2 Macrolides (n=171) 0.76 0.63–0.89 0.87 0.78–0.96 0.93 0.82–1.00
3 Quinolones (n=176) 0.79 0.69–0.88 0.89 0.82–0.96 0.93 0.87–0.98
4 Amoxicillin, doxycillin, nitrofurantoin (n=681) 0.81 0.78–0.87 0.86 0.85–0.92 0.92 0.90–0.98
1–4 Pooled antibiotics of indicators 1–4 (n=1,225) 0.83 0.77–0.88 0.89 0.86–0.94 0.93 0.92–0.98
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classify antimicrobial prescribing behavior correctly. We
found that our four indicators showed the best fit with
reality if we defined a “new prescription” as being issued at
least 35 days after the previous antimicrobial prescription
was issued (Cohen’s κ ≥ 0.90). This “clinical” classification
(based on patient files) was compared with a “technical”
classification, based on our indicators (which were to be
applied to a pharmaceutical database). When analyzing the
technical classification as a diagnostic test, the post-test
probability also showed very high values. This high score
legitimizes the use of 35 days as the cut-off value, with
only a low rate of misclassification remaining. In fact, most
misclassifications involved new prescriptions being classi-
fied as not new, which would mean they are not taken into
account when calculating the score for a particular quality
indicator.
Our study was subject to certain limitations. Firstly,
the results might not be representative of all family
practices in the Netherlands, since our study took place
in the southern part of the country only, and only in five
family practices. However, the population of practices
included in the RNH registration network are generally
well comparable to the Dutch population as a whole [10].
Secondly, the auditing of the medical files was done by a
student and not by an experienced doctor. However, this
was a senior medical student, who immediately after
completing this research project received his medical
degree and started vocational training in general practice.
Furthermore, the student discussed all problematic classi-
fications (3%) with the first author. The third limitation
was that we only compared results for three periods of
time: 35, 28, and 21 days, and not for periods longer than
35 days. Extending this period beyond 35 days would
definitely improve the accuracy of the concept of “new
prescription,” but would incorrectly exclude from the
numerator and denominator too many prescriptions that
were in fact new, thus affecting the validity as well as the
robustness of the indicator.
The strengths of our study were that the five practices we
visited differed in terms of location, population, and degree
of urbanization, and that the medical files in these practices
were audited by an independent senior medical student with
no conflict of interest.
Unfortunately, we found no other studies on this subject
at the time we performed our study to compare our results
with.
To put these findings into perspective, it is essential to
distinguish between the external and internal use of quality
indicators. Indicators for external use are intended to be
used by governments, patient organizations, or health
insurance companies, whereas internal indicators are main-
ly used by the health care providers themselves [6, 11].
They can use the information generated by quality
indicators to monitor the health care provided by them-
selves or the organization they belong to, and can
investigate the potential and current problems by reflecting
on these data [6]. In the case of disappointing quality, the
scores should be carefully analyzed to identify explanatory
factors, and if the data are correct and concern modifiable
factors, they can be used to improve the outcome. Given the
different purposes of internal and external indicators, they
need to meet different criteria [6, 11]. External indicators
need to have the highest validity, as they are used to judge
the work of medical professionals. Internal indicators also
need to be accurate, but since they are mainly used for self-
reflection and their results have no major consequences,
certain errors of measurement are acceptable. Our indica-
tors have a high validity but are not infallible, and we
recommend cautious application, merely for internal use.
In conclusion we can state that our indicators of the
quality of prescribing behavior show good validity and
accuracy for internal use if we define the term “new
prescription” as a prescription issued 35 days (5 weeks) or
more after the previous antimicrobial prescription was
issued.
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Table 4 Sensitivity, specificity, likelihood ratios for positive and
negative results, and pre-test and post-test probabilities for positive
and negative results, defining a “new prescription” as one issued 21,
28, and 35 days after a previous one
21 days 28 days 35 days
Sensitivity 0.987 0.980 0.976
Specificity 0.787 0.903 0.987
Likelihood ratio + 4.63 10.18 77.73
Likelihood ratio − 0.02 0.02 0.02
Pre-test probability + 0.805 0.805 0.805
Post-test probability + 0.948 0.976 0.997
Pre-test probability − 0.195 0.195 0.195
Post-test probability − 0.003 0.005 0.006
The likelihood ratio incorporates both the sensitivity and specificity of
the test and provides a direct estimate of how much a test result will
change the odds of having a certain property. The likelihood ratio for a
positive result (LR+) tells you how much the odds of the property
increase when a test is positive. The likelihood ratio for a negative
result (LR−) tells you how much the odds of the property decrease
when a test is negative. The pre-test probability is the proportion of
prescriptions that do or don’t have the target characteristic (“first” or
“not first” antibiotic). The post-test probability is the proportion of
prescriptions with that particular test result that have the target
characteristic
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